Tobacco smoking is the main preventable cause of morbidity and mortality in Australia. Recently published evidence-based guidelines for general practitioners recommend the 5As framework which is consistent with other international guidelines. Active follow-up of smokers by Quitline and the use of nurses to provide smoking cessation activities are two interventions that are likely to expand the reach of smoking cessation services and increase their effectiveness. Combination pharmacotherapies for nicotine dependence should be considered in smokers who have had difficulty quitting despite the concurrent use of brief behavioural counselling and pharmacotherapy.
Introduction
Every year in Australia, tobacco smoking causes an estimated 19 000 deaths and up to 10% of hospital separations in people aged 35 years and over. 1 The 50-year follow-up of the British doctors study shows that up to 66% of lifelong smokers are likely to die from a tobacco-related disease with half these deaths occurring prematurely. 2 No other single avoidable factor accounts for such a high proportion of deaths. 1 Health professionals have several strategies they can use to encourage patients to quit smoking. In addition to the publication of the first Australian smoking cessation guidelines for general practice in 2004 1 , there have been a number of other developments. These include:
■ increasing evidence for the effectiveness of: -active callback programs by the Quitline 3, 4 -nurses providing smoking cessation in the primary care setting 5 ■ the need to consider the use of combination pharmacotherapies in assisting smokers to quit. 6
Smoking cessation guidelines for Australian general practice
The Australian general practice guidelines for smoking cessation follow the 5As framework ( 
Nurse-delivered smoking cessation strategies
A systematic review has found that nurses have a similar impact to doctors when providing smoking cessation in primary care. 5 The main findings of the systematic review were:
■ smokers offered advice by a nurse had an increased likelihood of quitting compared to smokers without nursing intervention (3-4 extra quitters for each 100 counselled)
■ smoking intervention in the 13 trials involving non-hospitalised adults gave an approximately 80% increase in the odds of success ■ there was no evidence from indirect comparisons that higher intensity interventions were more effective in achieving successful quitting.
Overall, the results revealed that brief smoking cessation interventions provided by nurses significantly increase the odds of quitting compared to usual care.
Combination pharmacotherapies in assisting smokers to quit
With the slow fall in the prevalence of smoking, the current population of smokers represent a mix of 'hardened' smokers who have attempted to quit on a number of occasions and others, for example younger smokers. 8 Both groups are exposed to increasing community awareness of the harmful effects of smoking and expanding legislative changes to quit. Identification of readiness to change, level of nicotine dependence and number of previous quit attempts will assist the practitioner in the approach to cessation, especially the use of pharmacotherapy.
Like other pharmacological treatments, combination therapy using drugs with different modes of action has been tried with differing degrees of success. 6 Combination therapy can include 
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may have been little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. An early study of bivalirudin found that it caused less bleeding but had no greater efficacy than high-dose heparin in preventing ischaemic complications in patients having coronary angioplasty. 1 Development of the drug did not proceed, however when the results were reanalysed several years later they showed a statistical advantage for bivalirudin. 2 As the drugs used during the procedure had changed in the intervening years, there was a need to evaluate bivalirudin with the new approaches.
Bivalirudin
The REPLACE-2 trial randomised 6010 patients to receive bivalirudin or heparin plus a glycoprotein IIb/IIIa inhibitor. All patients also received aspirin and the use of clopidogrel was
